Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
This innovative synthetic peptide represents the next generation of metabolic therapeutics, demonstrating unprecedented efficacy in clinical trials for obesity and type 2 diabetes management
What Does Human Research Actually Say
Modest Human Weight Loss (Phase 2 Data) Evidence quality: Moderate (one phase 2b trial, 300 patients) In a 12-week, randomized, double-blind, placebo-controlled trial with 300 obese adults across five sites, oral AOD-9604 produced measurable but modest weight loss
There are two 2HG enantiomers: D-2-hydroxyglutarate (D2HG) and L-2-hydroxyglutarate (L2HG), with the former predominantly generated from IDH1 mutants and PHGDH while L2HG is primarily generated from the promiscuous activity of LDHA and MDH1/2 under hypoxic or acidic conditions and converted back to 2OG by L2HGDH
